HT 3951

Drug Profile

HT 3951

Alternative Names: HT-3951

Latest Information Update: 12 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Helicon Therapeutics
  • Developer Dart NeuroScience
  • Class Isoxazoles
  • Mechanism of Action Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Stroke

Most Recent Events

  • 03 Dec 2015 Phase-II clinical trials in Stroke (In the elderly, In adults) in USA (PO)
  • 13 Apr 2015 Phase-I clinical trials in Neurodegenerative disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top